Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Correction: Trinh, H.V., et al. Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. Cells 2019, 8, 365.

Trinh HV, Gohain N, Pham PT, Hamlin C, Song H, Sanders-Buell E, Bose M, Eller LA, Jain S, Uritskiy G, Rao VB, Tovanabutra S, Michael NL, Robb ML, Joyce MG, Rao M.

Cells. 2019 Jun 6;8(6). pii: E554. doi: 10.3390/cells8060554.

2.

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators.

J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23.

3.

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.

Peachman KK, Karasavvas N, Chenine AL, McLinden R, Rerks-Ngarm S, Jaranit K, Nitayaphan S, Pitisuttithum P, Tovanabutra S, Zolla-Pazner S, Michael NL, Kim JH, Alving CR, Rao M.

PLoS One. 2015 Dec 1;10(12):e0143895. doi: 10.1371/journal.pone.0143895. eCollection 2015.

5.

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang KK, Gurley TC, Kozink DM, Armand LC, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, O'Connell RJ, Kim JH, Michael NL, Montefiori DC, Tomaras GD, Liao HX, Haynes BF, Ferrari G.

J Virol. 2014 Jul;88(14):7715-26. doi: 10.1128/JVI.00156-14. Epub 2014 May 7.

6.
7.
8.

Sera from HIV-1 infected individuals in all stages of disease preferentially recognize the V3 loop of the prototypic macrophage-tropic glycoprotein gp120 ADA.

Ebenbichler C, McNearney T, Stoiber H, Möst J, Zangerle R, Vogetseder W, Patsch JR, Ratner L, Dierich MP.

Mol Immunol. 1995 Oct;32(14-15):1039-45.

PMID:
8544853
9.

Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.

Powell RLR, Totrov M, Itri V, Liu X, Fox A, Zolla-Pazner S.

J Virol. 2017 Aug 10;91(17). pii: e00410-17. doi: 10.1128/JVI.00410-17. Print 2017 Sep 1.

10.

Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys.

Nguyen QN, Martinez DR, Himes JE, Whitney Edwards R, Han Q, Kumar A, Mangan R, Nicely NI, Xie G, Vandergrift N, Shen X, Pollara J, Permar SR.

Retrovirology. 2018 Mar 9;15(1):24. doi: 10.1186/s12977-018-0406-5.

12.

Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.

Gu L, Krendelchtchikova V, Krendelchtchikov A, Farrow AL, Derdeyn CA, Matthews QL.

Virology. 2016 Jan;487:75-84. doi: 10.1016/j.virol.2015.10.010. Epub 2015 Oct 23.

13.

Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, Beaumont D, Shen X, Yates NL, Pinter A, Tomaras GD, Ferrari G, Montefiori DC, Hu SL.

J Virol. 2016 Sep 12;90(19):8644-60. doi: 10.1128/JVI.00853-16. Print 2016 Oct 1.

14.
15.

Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.

Babas T, Benichou S, Guetard D, Montagnier L, Bahraoui E.

Mol Immunol. 1994 Apr;31(5):361-9.

PMID:
8152439
16.

Humoral immunogenicity of an HIV-1 envelope residue 649-684 membrane-proximal region peptide fused to the plague antigen F1-V.

Matoba N, Shah NR, Mor TS.

Vaccine. 2011 Aug 5;29(34):5584-90. doi: 10.1016/j.vaccine.2011.06.007. Epub 2011 Jul 13.

17.

Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.

Doran RC, Morales JF, To B, Morin TJ, Theolis R Jr, O'Rourke SM, Yu B, Mesa KA, Berman PW.

Mol Immunol. 2014 Nov;62(1):219-226. doi: 10.1016/j.molimm.2014.06.025. Epub 2014 Jul 11.

19.
20.

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.

Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

PLoS One. 2018 Dec 19;13(12):e0208345. doi: 10.1371/journal.pone.0208345. eCollection 2018.

Supplemental Content

Support Center